BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

Advertising powered by artificial intelligence is a core part of Chief Executive Mark Zuckerberg's vision for the company's future. BioNTech and Bristol Myers Squibb have agreed to jointly develop and ...

Escalating investor concern now surrounds Elon Musk's scattered focus, particularly as Tesla's sales slump, its stock ...

With Tesla’s future hanging in the balance, a heated debate is emerging over whether the electric vehicle (EV) revolution can ...

Tesla sales in the EU slumped for a fourth consecutive month as Musk’s EV maker struggled to cash in on a growing market in ...

Tesla outsold all major rivals by a large margin in Q1 2025. Here's why so many drivers are still choosing Tesla EVs over alternatives.

Electric car sales are booming in Europe—but not for Tesla. The Elon Musk–led automaker’s sales continue to decline in the ...

According to new figures from the European Automobile Manufacturers' Association (ACEA), Tesla sold 7,261 cars in Europe in ...

Tesla's brand is the focus of a backlash against CEO Elon Musk for his political views and involvement with President Trump's ...

Tesla’s (NASDAQ:TSLA) grip on the European electric vehicle market weakened sharply in April, as the U.S. automaker faces ...

Tesla’s much-anticipated Model Y refresh isn’t generating the buzz many expected, leaving the EV giant scrambling for answers ...

Rivian has struggled to grow sales. Elon Musk's political moves have weighed on Tesla, which investors hope will give Rivian ...